© Reuters. FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski/File Photo
(Corrects AstraZeneca (NASDAQ:)’s spelling in the headline)
(Reuters) -AstraZeneca said on Tuesday it had agreed to buy China-based Gracell Biotechnologies to support its cell therapy ambitions, in a deal valued at approximately $1.2 billion.
